Olsonoconnor8531

Plastic products have played significant roles in protecting people during the COVID-19 pandemic. The widespread use of personal protective gear created a massive disruption in the supply chain and waste disposal system. Millions of discarded single-use plastics (masks, gloves, aprons, and bottles of sanitizers) have been added to the terrestrial environment and could cause a surge in plastics washing up the ocean coastlines and littering the seabed. This paper attempts to assess the environmental footprints of the global plastic wastes generated during COVID-19 and analyze the potential impacts associated with plastic pollution. The amount of plastic wastes generated worldwide since the outbreak is estimated at 1.6 million tonnes/day. We estimate that approximately 3.4 billion single-use facemasks/face shields are discarded daily as a result of COVID-19 pandemic, globally. Our comprehensive data analysis does indicate that COVID-19 will reverse the momentum of years-long global battle to reduce plastic waste pollution. As governments are looking to turbo-charge the economy by supporting businesses weather the pandemic, there is an opportunity to rebuild new industries that can innovate new reusable or non-plastic PPEs. The unanticipated occurrence of a pandemic of this scale has resulted in unmanageable levels of biomedical plastic wastes. This expert insight attempts to raise awareness for the adoption of dynamic waste management strategies targeted at reducing environmental contamination by plastics generated during the COVID-19 pandemic.COVID-19, caused by SARS-CoV-2, a new coronavirus, was first observed in Wuhan (China) in November 2019. In a short time, SARS-CoV-2 spread across the world, creating a pandemic. There is a need to know the current situation of each country and region and to generate strategies to contain and mitigate the impact on global health and the economy. To control COVID-19 in Cartagena and the Department of Bolívar, Colombia, a strategic network involving public health entities and higher education institutions has emerged. The network has been in place for six months, and 77,122 subjects have been tested in Cartagena and Bolívar Department, of whom 8,260 (10.71%) tested positive (RT-qPCR). Of those who tested positive, 51.4% were male (p>0.05), and 13.1% were health personnel (9.43% female, p 0.05). The daily case report showed upward and downward fluctuations by the mobility restrictions applied to the population, and from day 120 of the start of the pandemic, the epidemiological curve stabilized, and a logarithmic plateau was reached. COVID-19 spread in 39/46 municipalities of Bolívar; however, Bolívar and Cartagena had a low number of cases and deaths compared to other departments and city in Colombia. Cartagena and Bolívar have been given an economic opening with restrictions on crowding and mandatory use of a mouth cover until a vaccine is available. UNIMOL was the first laboratory in Cartagena, Bolívar and Colombia to receive approval from the National Institute of Health to process COVID-19 samples; thanks to the timely diagnosis of cases by UNIMOL, intensive care unit (ICU) occupancy did not exceed capacity, and population confinement was appropriately initiated.The COVID-19 situation had escalated into an unprecedented global crisis in just a few weeks. On the 30th of January 2020, World Health Organization officially declared the COVID-19 epidemic as a public health emergency of international concern. The confirmed cases were reported to exceed 105,856,046 globally, with the death toll of above 2,311,048, according to the dashboard from Johns Hopkins University on the 7th of February, 2021, though the actual figures may be much higher. Conserved regions of the South Asian strains were used to construct a phylogenetic tree to find evolutionary relationships among the novel virus. Off target similarities were searched with other microorganisms that have been previously reported using Basic Local Alignment Search Tool (BLAST). The conserved regions did not match with any previously reported microorganisms or viruses, which confirmed the novelty of SARS-CoV-2. Currently there is no approved drug for the prevention and treatment of COVID-19, but researchers globally are attempting to come up with one or more soon. Therapeutic strategies need to be addressed urgently to combat COVID-19. Successful drug repurposing is a tool that uses old and safe drugs, is time effective and requires lower development costs, and was thus considered for the study. Molecular docking was used for repurposing drugs from our own comprehensive database of approximately 300 highly characterized, existing drugs with known safety profile, to identify compounds that will inhibit the chosen molecular targets - SARS-CoV-2, ACE2, and TMPRSS2. The study has identified and proposed twenty seven candidates for further in vitro and in vivo studies for the treatment of SARS-CoV-2 infection.Quantifying the ratio of alternatively spliced mRNA variants of genes with known alternative splicing variants is highly relevant for many applications. Herein, we describe the validation of a quantitative PCR design for the simplified quantification of known mRNA splice variants. The assay uses a single-common primer pair, dual probe design for the determination of splicing variants in a single well configuration. We used murine XBP-1 splicing variants, XBP-1S and XBP-1U, to validate and demonstrate the performance characteristics of this approach. Using synthetic XBP-1S and XBP-1U cDNA as well as cDNA synthesized from mouse beta-cell line MIN6, we established the performance parameters and dynamic range of the assay. Reliable quantification of both variants at varying concentration gradients was shown. No cross detection of XBP-1U by the XBP-1S probe was detected and only marginal XBP-1S cross detection by the XBP-1U probe was detected at high concentration gradients that are unlikely to be relevant. We demonstrated that the assay accurately detected changes of XBP-1 splice variants in mouse liver subjected to pharmacologically induced ER stress without the need for normalization to a reference gene.

Home-based care (HBC) is a valuable tool to provide care to rural, medically underserved populations. By mitigating geographic and transportation barriers for vulnerable populations, HBC is a promising modality of health care delivery. Interprofessional education has become an integral part in undergraduate and professional curricula; however, applications of team-based training in HBC are often missing from curricula. When included, instruction in HBC often utilizes didactic instruction or laboratory experiences, which are discipline-specific and lack a focus on integration of team-based care.

We implemented a standardized patient (SP) simulation of a posthospital discharge home visit using a team of learners from nursing, physical therapy (PT), occupational therapy (OT), dentistry, pharmacy, and medicine in a simulated home environment. Pre- and postsimulation competencies of interprofessional care were measured using the 20-item Interprofessional Collaborative Competency Attainment Survey (ICCAS).

Throughout the academic years of August 2018 - August 2020, 68 students from nursing, PT, OT, pharmacy, medicine, and dentistry completed a simulated home visit with an SP discharged from a hospital. For all 20 perceived abilities on the ICCAS, learners showed a statistically significant increase in postsurvey measurement. A modest to large (.31 ≤

≤ .94) effect size was observed in the majority of responses.

This SP simulation described a novel, interdisciplinary approach to incorporating HBC into interprofessional curricula.

This SP simulation described a novel, interdisciplinary approach to incorporating HBC into interprofessional curricula.

Children with disabilities are particularly vulnerable to school failure, as they are more likely than their peers to experience school dropout and academic struggles. Early identification of learning difficulties and access to special education services are critical to the success of children with disabilities. However, few pediatricians feel competent in screening for risks of school failure and/or assisting families with navigating the special education system. Due to restricted duty hours and limited scheduled didactic time during residency, flexible training options are needed to fill this educational gap and address this systems-based practice competency.

We developed a 30-minute self-paced virtual learning module aimed at educating pediatric residents on strategies for navigating the special education system. The module used a knowledge, attitudes, and self-efficacy framework, as well as case examples and pictorial relationships to illustrate concepts. Wilcoxon signed rank tests were conducted to athe special education system.[This corrects the article DOI 10.1021/acscentsci.0c00855.].Therapeutic immunotoxins composed of antibodies and bacterial toxins provide potent activity against malignant cells, but joining them with a defined covalent bond while maintaining the desired function is challenging. Here, we develop novel immunotoxins by dovetailing full-length immunoglobulin G (IgG) antibodies and nontoxic anthrax proteins, in which the C terminus of the IgG heavy chain is connected to the side chain of anthrax toxin protective antigen. This strategy enabled efficient conjugation of protective antigen variants to trastuzumab (Tmab) and cetuximab (Cmab) antibodies. The conjugates effectively perform intracellular delivery of edema factor and N terminus of lethal factor (LFN) fused with diphtheria toxin and Ras/Rap1-specific endopeptidase. Each conjugate shows high specificity for cells expressing human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), respectively, and potent activity across six Tmab- and Cmab-resistant cell lines. The conjugates also exhibit increased pharmacokinetics and pronounced in vivo safety, which shows promise for further therapeutic development.Holes (h + ) on heterogeneous photocatalysts could act as important oxidative species or precursors for reactive oxygen species (ROS). However, due to the ultrafast recombination of photoinduced electrons and holes, a majority of carriers are consumed prior to surface reactions. Herein, we report an unprecedented nonphotomediated hole oxidation system constructed from carbon nanotubes (CNTs) and superoxides. This system exhibited high catalytic activity for the degradation of organic pollutants, which outperforms the classical oxidation processes in the remediation of actual wastewater and is comparable to that of the best single cobalt atom catalyst. Theoretical and experimental results reveal that the intrinsic defects with unpaired spins on CNTs served as adsorptive sites to activate superoxides. This is the first report on exploring the oxidation properties of nonphotomediated hole carriers on heterogeneous catalysts, which will be of broad interest for researchers in environmental remediation, chemical synthesis, and biological fields.The maintenance of therapeutic glycoproteins within the circulatory system is associated, in large part, with the integrity of sialic acids as terminal sugars on the glycans. Glycoprotein desialylation, either by spontaneous cleavage or through host sialidases, leads to protein clearance, mainly through the liver. Thus, the installation of minimally modified sialic acids that are hydrolysis-resistant yet biologically equivalent should lead to increased circulatory half-lives and improved pharmacokinetic profiles. Here we describe the chemoenzymatic synthesis of CMP-sialic acid sugar donors bearing fluorine atoms at the 7-position, starting from the corresponding 4-deoxy-4-fluoro-N-acetylhexosamine precursors. For the derivative with natural stereochemistry we observe efficient glycosyl transfer by sialyltransferases, along with improved stability of the resultant 7-fluorosialosides toward spontaneous hydrolysis (3- to 5-fold) and toward cleavage by GH33 sialidases (40- to 250-fold). Taking advantage of the rapid transfer of 7-fluorosialic acid by sialyltransferases, we engineered the O-glycan of Interferon α-2b and the N-glycans of the therapeutic glycoprotein α1-antitrypsin.